News for Arrowhead Pharmaceuticals, Inc. (ARWR)

Arrowhead Pharmaceuticals, Snowflake, Dover and Fluor are each in focus on today's edition of

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has initiated the human trial of ARO-ALK7, a novel RNA interference (RNAi) therapeutic targeting adipose-specific gene expression to combat obesity.

Summary Arrowhead Pharmaceuticals Inc (ARWR) announced on [date] the commencement of a Phase 1/2a clinical trial for ARO-ALK7, an investigational RNA interferen

Arrowhead Pharmaceuticals has initiated a Phase 1/2a clinical trial for its experimental RNA interference therapy, ARO-ALK7, aimed at addressing obesity. Design

Arrowhead Pharmaceuticals (ARWR) has begun a Phase 1/2a trial for its RNAi therapeutic, ARO-ALK7, targeting obesity treatment. ARO-ALK7 aims to silence the

Summary Arrowhead Pharmaceuticals Inc (ARWR), a company specializing in RNA interference-based therapeutics, announced its participation in two significant inve

Arrowhead Pharmaceuticals (ARWR) to participate in two major investor conferences in June 2025. Engagements include Jefferies Global Healthcare Conferen

UBS has revised its price target for Arrowhead (ARWR), decreasing it from $71 to $63. Despite this adjustment, the firm maintains its Buy rating on the stock, i

Arrowhead Pharmaceuticals (ARWR) finds itself in the spotlight as Citigroup analyst Shawn Egan has adjusted the company's stock price target while maintaining a

ZeroHedge - On a long enough timeline, the survival rate for everyone drops to zero

Shares of Coinbase Global, Inc. COIN rose sharply in today's pre-market trading. Coinbase is set to join the S&P 500, replacing Discover Financial Services DFS...

Net Income: $370.4 million or $2.75 per share for the quarter ended March 31, 2025.Revenue: $542.7 million for the quarter ended March 31, 2025.Operating Expen

Arrowhead Pharmaceuticals Inc (ARWR) reports a significant increase in net income, showcasing robust financial health.Strategic collaboration with Sarepta Ther

May 12, 2025 / 08:30PM GMTOperator Ladies and gentlemen, welcome to the Arrowhead Pharmaceuticals Conference Call. (Operator Instructions) I will now hand the c

Summary: Arrowhead Pharmaceuticals is nearing its commercial-stage debut with plozasiran. Analysts foresee significant upside potential with an average t

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q2 2025 Earnings Conference Call May 12, 2025 4:30 PM ETCompany ParticipantsVincent Anzalone - Vice President...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2025 second quarter ended March 31, 2025. The Company is hostin

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the first quarter 20

We recently published a list of Top 11 Small Cap Stocks to Buy with Biggest Upside Potential. In this article, we are going to take a look at where Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) stands against other top small cap stocks to buy with biggest upside potential. On April 24, Jill Carey Hall, BofA Securities head […]